Targeting Upstream Mediators and the Airway Epithelium With Next-Generation Biologics

VIRTUAL EXAM ROOM RESOURCE GUIDE

RECENT GUIDELINE RECOMMENDATIONS FOR SEVERE ASTHMA

2022 GINA Report, Global Strategy for Asthma Management and Prevention

CLINICAL TRIALS

Approved Agents

Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial

Tezepelumab in Adults with Uncontrolled Asthma (PATHWAY Trial)

Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma (NAVIGATOR Trial)

Investigational Agents

Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma

Astegolimab (anti-ST2) Efficacy and Safety in Adults With Severe Asthma: A Randomized Clinical Trial

REAL-WORLD TRIALS AND SEVERE ASTHMA REGISTRIES

CHRONICLE Study

The International Severe Asthma Registry

OPTIMIZING PATIENT TREATMENT & OUTCOMES

Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study

The Airway Epithelium—A Central Player in Asthma Pathogenesis

Airway Hyperresponsiveness in Asthma: Its Measurement and Clinical Significance

ROLE OF EPITHELIAL ALARMINS IN SEVERE ASTHMA

Click image to view animation



INTEGRITY CONTINUING EDUCATION
www.integrityce.com

This program is provided by Integrity Continuing Education, Inc.
This program is supported by an educational grant from AstraZeneca Pharmaceuticals.